8BQ3
 
 | |
5LCN
 | |
5G5M
 | |
5G5C
 | |
5G59
 | |
7P47
 | | Structure of the E3 ligase Smc5/Nse2 in complex with Ubc9-SUMO thioester mimetic | | Descriptor: | E3 SUMO-protein ligase MMS21, SUMO-conjugating enzyme UBC9, Structural maintenance of chromosomes protein 5, ... | | Authors: | Lascorz, J, Varejao, N, Reverter, D. | | Deposit date: | 2021-07-09 | | Release date: | 2021-11-24 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (3.314 Å) | | Cite: | Structural basis for the E3 ligase activity enhancement of yeast Nse2 by SUMO-interacting motifs.
Nat Commun, 12, 2021
|
|
6XTK
 | | Y114C Transthyretin structure in complex with Tolcalpone | | Descriptor: | Tolcapone, Transthyretin | | Authors: | Varejao, N, Reverter, D, Pinheiro, F, Pallares, I, Ventura, S. | | Deposit date: | 2020-01-16 | | Release date: | 2020-05-13 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.7 Å) | | Cite: | Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Febs J., 288, 2021
|
|
7QC5
 | | Crystal structure of human wild type transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound | | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-[3-nitro-4,5-bis(oxidanyl)phenyl]methanone, Transthyretin | | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | | Deposit date: | 2021-11-22 | | Release date: | 2022-11-30 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (1.2 Å) | | Cite: | Development of a Highly Potent Transthyretin Amyloidogenesis Inhibitor: Design, Synthesis, and Evaluation.
J.Med.Chem., 65, 2022
|
|
6TXW
 | | V30G Transthyretin structure in complex with Tolcalpone | | Descriptor: | Tolcapone, Transthyretin | | Authors: | Varejao, N, Reverter, D, Pinheiro, F, Pallares, I, Ventura, S. | | Deposit date: | 2020-01-14 | | Release date: | 2020-05-13 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.153 Å) | | Cite: | Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Febs J., 288, 2021
|
|
6TXV
 | | A25T Transthyretin structure in complex with Tolcalpone | | Descriptor: | Tolcapone, Transthyretin | | Authors: | Varejao, N, Reverter, D, Pinheiro, F, Pallares, I, Ventura, S. | | Deposit date: | 2020-01-14 | | Release date: | 2020-05-13 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.6 Å) | | Cite: | Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Febs J., 288, 2021
|
|
5FO2
 | | Structure of human transthyretin mutant A108I | | Descriptor: | TRANSTHYRETIN | | Authors: | Varejao, N, Santanna, R, Saraiva, M.J, Gallego, P, Ventura, S, Reverter, D. | | Deposit date: | 2015-11-17 | | Release date: | 2016-11-30 | | Last modified: | 2024-05-08 | | Method: | X-RAY DIFFRACTION (1.449 Å) | | Cite: | Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.
Sci Rep, 7, 2017
|
|
6FWW
 | | GFP/KKK. A redesigned GFP with improved solubility | | Descriptor: | Green fluorescent protein | | Authors: | Varejao, N, Lascorz, J, Gil-Garcia, M, Diaz-Caballero, M, Navarro, S, Ventura, S, Reverter, D. | | Deposit date: | 2018-03-07 | | Release date: | 2018-08-01 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (1.131 Å) | | Cite: | Combining Structural Aggregation Propensity and Stability Predictions To Redesign Protein Solubility.
Mol. Pharm., 15, 2018
|
|
6FXU
 | |
8PM9
 | | Crystal structure of human wild type transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) | | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone, Transthyretin | | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | | Deposit date: | 2023-06-28 | | Release date: | 2024-05-08 | | Method: | X-RAY DIFFRACTION (1.85 Å) | | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties.
Eur.J.Med.Chem., 261, 2023
|
|
8PMA
 | | Crystal structure of human V30M transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) | | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone, Transthyretin | | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | | Deposit date: | 2023-06-28 | | Release date: | 2024-05-08 | | Method: | X-RAY DIFFRACTION (1.2 Å) | | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties.
Eur.J.Med.Chem., 261, 2023
|
|
8PM8
 | | V30M Transthyretin structure in complex with Tolcalpone | | Descriptor: | Tolcapone, Transthyretin | | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | | Deposit date: | 2023-06-28 | | Release date: | 2024-05-08 | | Method: | X-RAY DIFFRACTION (1.57 Å) | | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties.
Eur.J.Med.Chem., 261, 2023
|
|
8PMO
 | | Crystal structure of human V122I transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) | | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone, Transthyretin | | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | | Deposit date: | 2023-06-29 | | Release date: | 2024-05-08 | | Method: | X-RAY DIFFRACTION (1.24 Å) | | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties.
Eur.J.Med.Chem., 261, 2023
|
|
5FW6
 | | Structure of human transthyretin mutant A108V | | Descriptor: | TRANSTHYRETIN | | Authors: | Gallego, P, Varejao, N, Santanna, R, Saraiva, M.J, Ventura, S, Reverter, D. | | Deposit date: | 2016-02-12 | | Release date: | 2017-03-08 | | Last modified: | 2024-05-08 | | Method: | X-RAY DIFFRACTION (1.3 Å) | | Cite: | Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.
Sci Rep, 7, 2017
|
|
5FW8
 | | Structure of human transthyretin mutant E89K | | Descriptor: | TRANSTHYRETIN | | Authors: | Gallego, P, Varejao, N, Santanna, R, Saraiva, M.J, Ventura, S, Reverter, D. | | Deposit date: | 2016-02-12 | | Release date: | 2016-12-28 | | Last modified: | 2024-05-08 | | Method: | X-RAY DIFFRACTION (1.6 Å) | | Cite: | Structure of New Non-Amyloidogenic Mutant of Ttr A108V
To be Published
|
|
6FZL
 | |
6FWD
 | |
5FW7
 | | Structure of human transthyretin mutant A109V | | Descriptor: | TRANSTHYRETIN | | Authors: | Gallego, P, Varejao, N, Santanna, R, Saraiva, M.J, Ventura, S, Reverter, D. | | Deposit date: | 2016-02-12 | | Release date: | 2017-03-08 | | Last modified: | 2024-05-08 | | Method: | X-RAY DIFFRACTION (1.2 Å) | | Cite: | Structure of New Non-Amyloidogenic Mutant of Ttr A108V
To be Published
|
|
8RQI
 | | Structure of Rhizobium NopD with ubiquitin | | Descriptor: | NopD, Polyubiquitin-B, prop-2-en-1-amine | | Authors: | Reverter, D, Li, Y. | | Deposit date: | 2024-01-18 | | Release date: | 2024-11-20 | | Method: | X-RAY DIFFRACTION (1.94 Å) | | Cite: | Broad-spectrum ubiquitin/ubiquitin-like deconjugation activity of the rhizobial effector NopD from Bradyrhizobium (sp. XS1150).
Commun Biol, 7, 2024
|
|
7P99
 | | Structure of human USPL1 in complex with SUMO2 | | Descriptor: | SUMO-specific isopeptidase USPL1, Small ubiquitin-related modifier, ZINC ION | | Authors: | Reverter, D, Ying, L. | | Deposit date: | 2021-07-26 | | Release date: | 2022-03-02 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Structural basis for the SUMO protease activity of the atypical ubiquitin-specific protease USPL1.
Nat Commun, 13, 2022
|
|
8OI3
 | | Structure of NopD with AtSUMO2 | | Descriptor: | Small ubiquitin-related modifier 2, Type III effector, prop-2-en-1-amine | | Authors: | Reverter, D, Li, Y. | | Deposit date: | 2023-03-22 | | Release date: | 2024-04-03 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (1.5 Å) | | Cite: | Broad-spectrum ubiquitin/ubiquitin-like deconjugation activity of the rhizobial effector NopD from Bradyrhizobium (sp. XS1150).
Commun Biol, 7, 2024
|
|
